Clinical trials
Follicular Lymphoma Grade 3A clinical trials
Below are recruiting follicular lymphoma grade 3a clinical trials, each written for real people, not researchers. We’re tracking 34 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06442475RecruitingPhase 2
Low-dose mosunetuzumab for untreated indolent B-cell lymphoma
This trial tests a low dose of the drug mosunetuzumab for people with slow-growing B-cell lymphomas (follicular lymphoma or marginal zone lymphoma) who have not had any previous treatment. It aims to see if this drug can help control the disease with fewer side effects.
Seattle, WashingtonAges 18 years+ - NCT07562022RecruitingPhase 3
SCTB35 Plus Lenalidomide for Resistant Follicular Lymphoma
This trial tests a new drug called SCTB35 combined with lenalidomide (a known cancer drug) in people whose follicular lymphoma (a type of blood cancer) has stopped responding to or come back after previous treatments. The combination may help shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–80 - NCT05389293RecruitingPhase 2
Mosunetuzumab with or without zanubrutinib for follicular lymphoma
This trial studies mosunetuzumab alone or combined with zanubrutinib to treat people with follicular lymphoma that is advanced or causing problems. It’s meant to see which approach works better and is safe for long-term treatment.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05045664RecruitingPhase 3
New follicular lymphoma treated with radiation plus antibody
This trial studies whether adding a targeted antibody to standard radiation can help people with early-stage, newly diagnosed follicular lymphoma. It aims to control the lymphoma more effectively while keeping treatment safe.
BerlinAges 18 years+ - NCT06471738RecruitingPhase 2
Targeted drug combo for untreated follicular lymphoma
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, and venetoclax) for people with untreated follicular lymphoma. The goal is to see if this combination works better than standard treatments and has manageable side effects.
BeijingAges 18 years+ - NCT03190928Recruiting
Study of lymphoma changes over time in follicular lymphoma
This study looks at how follicular lymphoma cells change (“clonal evolution”) over time. It may help doctors understand disease behavior and guide better future treatments, especially when people may need treatment soon.
Bethesda, MarylandAges 18 years+ - NCT04792502RecruitingPhase 2
Mosunetuzumab plus lenalidomide for untreated follicular or marginal lymphoma
This Phase 2 study tests whether mosunetuzumab, added to lenalidomide, can treat people who have not yet received lymphoma medicines. It’s for follicular lymphoma or marginal zone lymphoma and may help shrink tumors and improve control of the disease.
New Haven, ConnecticutAges 18 years+ - NCT04834024RecruitingPhase 3
MIL62 plus lenalidomide vs lenalidomide alone for rituximab-refractory lymphoma
This trial tests whether adding MIL62 to lenalidomide works better than lenalidomide alone in people with follicular lymphoma that no longer responds to rituximab. The goal is to improve tumor control by using an additional medicine along with standard treatment.
BeijingAges 18 years+ - NCT04883437RecruitingPhase 2
Acalabrutinib plus obinutuzumab for slow-growing lymphoma
This Phase 2 study tests two medicines together—acalabrutinib and obinutuzumab—in people with previously untreated, slow-growing B-cell lymphomas. It aims to shrink the lymphoma and improve disease control, especially when tumor burden is low or when standard first treatments aren’t suitable.
Atlanta, GeorgiaAges 18 years+ - NCT04989621RecruitingPhase 2
Orelabrutinib plus rituximab for relapsed follicular lymphoma
This Phase 2 study tests whether orelabrutinib combined with rituximab, followed by orelabrutinib alone for a while, can control follicular lymphoma that has come back or did not respond. It may help shrink tumors and keep the disease from worsening after initial response.
Guangzhou, GuangdongAges 18 years+ - NCT04998669RecruitingPhase 2
Loncastuximab plus rituximab for relapsed follicular lymphoma
This Phase 2 study tests whether loncastuximab, combined with rituximab, can shrink and control follicular lymphoma that has come back or not responded to prior treatment. It may help people who still have active disease that needs treatment and meet specific scan and blood test requirements.
Fort Myers, FloridaAges 18 years+ - NCT05326243RecruitingPhase 1/Phase 2
CAR-T therapy for hard-to-treat B-cell lymphoma
This trial tests a CAR-T cell treatment made to target CD19 on lymphoma cells (PL001). It’s for people whose B-cell lymphoma has come back or not responded to standard treatments, aiming to shrink the cancer and help control the disease.
Taipei, TaiwanAges 14 years+ - NCT05377307Recruiting
Long-term follow-up for gene-edited immune cell therapy
This study checks how people are doing years after receiving a specific company’s gene-edited immune cell treatment. It helps researchers learn about long-term safety and health outcomes.
Kaohsiung, TaiwanAges Any age - NCT06026319RecruitingPhase 1
CAR T cells targeting CD79b and CD19 for non-Hodgkin lymphoma
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It's for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments.
Boston, MassachusettsAges 18 years+ - NCT06453044RecruitingPhase 2
Study of two drugs for follicular lymphoma that came back
This study tests a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) for people with follicular lymphoma that has come back or not responded to previous treatment. The goal is to see if this two-drug approach can help shrink tumors and control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06704555RecruitingPhase 2
Radiation plus drug combo for untreated bulky follicular lymphoma
This trial tests a combination of radiation, an immunotherapy drug (tislelizumab), and chemotherapy (RCHOP) for people with previously untreated bulky follicular lymphoma. It aims to see if giving radiation first followed by the drug combo can improve outcomes for larger tumors.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06826118RecruitingPhase 2
Car t-cell therapy for relapsed follicular lymphoma
This trial tests a new car t-cell treatment (axicabtagene ciloleucel) for people with follicular lymphoma that has come back or not responded after at least two prior treatments. It aims to see if this therapy can help control the lymphoma.
Xiamen, FujianAges 18 years+ - NCT06859008RecruitingPhase 1
Zanubrutinib and sonrotoclax for B-cell lymphoma in diverse groups
This trial tests two targeted drugs, zanubrutinib and sonrotoclax, together for people with certain types of B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. It focuses on enrolling patients from racial and ethnic groups that are often underrepresented in research.
Duarte, CaliforniaAges 18 years+ - NCT06948786RecruitingPhase 2
Pirtobrutinib and Mosunetuzumab for relapsed follicular lymphoma
This trial tests two new drugs, pirtobrutinib and mosunetuzumab, for people with follicular lymphoma that has come back or not responded to earlier treatments. The goal is to see if this combination can help control the cancer.
Seattle, WashingtonAges 18 years+ - NCT07299149RecruitingPhase 2
Testing a new triple-drug combination for untreated follicular lymphoma
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
Tianjin, Tianjin MunicipalityAges 18–90 - NCT07545603RecruitingPhase 2
XNW5004 tablets for hard-to-treat follicular lymphoma
This study tests a new tablet called XNW5004 in patients with follicular lymphoma (a type of blood cancer) that has come back or stopped responding after multiple prior treatments. The goal is to see if this drug can help control the cancer in patients who have limited options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06284122RecruitingPhase 3
New drug combo vs standard chemo for untreated follicular lymphoma
This study tests a new combination of two drugs (mosunetuzumab and lenalidomide) compared to standard chemo-immunotherapy for people with newly diagnosed follicular lymphoma that needs treatment. It aims to see if the new combination works better and has fewer side effects.
GrazAges 18 years+ - NCT06350318RecruitingPhase 2
Rituximab and Zanubrutinib for slow-growing B-cell lymphomas
This trial tests a combination of two targeted drugs (rituximab and zanubrutinib) for people with slow-growing B-cell lymphomas like marginal zone or follicular lymphoma. It may be a good option if you haven't had treatment for your lymphoma before and your disease needs therapy to manage symptoms.
Tampa, FloridaAges 18 years+ - NCT04669171RecruitingPhase 1/Phase 2
Vaccine treatment for slow-growing lymphoma, alone or combined
This trial tests a new vaccine medicine (EO2463) to treat indolent non-Hodgkin lymphoma (slow-growing lymphoma), either by itself or with other treatment. It may help your immune system recognize and attack lymphoma cells.
Boston, MassachusettsAges 18 years+
Hear when a new Follicular Lymphoma Grade 3A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for follicular lymphoma grade 3a?
- Yes. Clin2 currently lists 34 recruiting follicular lymphoma grade 3a studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a follicular lymphoma grade 3a trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a follicular lymphoma grade 3a trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.